In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
no speaker photo
Speaker
Stefan Anker
Stefan Anker Stefan Anker

Charite - Campus Benjamin Franklin, Berlin (Germany)

Speciality : Acute Heart Failure

114 presentations from this speaker

ASPIRE.

Event : HFA Discoveries 2020

  • Session : Why we should embrace SGLT2 inhibitors for heart failure
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Co Alliance

COMMUNITY.

Event : HFA Discoveries 2020

  • Session : Why we should embrace SGLT2 inhibitors for heart failure
  • Speaker : M Cowie (London,GB), R Fontes Carvalho (Porto,PT), S Anker (Berlin,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Co Alliance

Why we should embrace SGLT2 inhibitors for heart failure

Event : HFA Discoveries 2020

  • Session : Why we should embrace SGLT2 inhibitors for heart failure
  • Speaker : M Cowie (London,GB), R Fontes Carvalho (Porto,PT), S Anker (Berlin,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Co Alliance

Addressing knowledge gaps: ongoing research on iron deficiency in chronic and acute heart failure.

Event : Heart Failure 2019

  • Session : Management of iron deficiency in heart failure: implementing best practices to improve patient outcomes
  • Speaker : S Anker (Berlin,DE)
  • Organised by MedEd Global Solutions & Charité Universitätsmedizin Berlin, supported with an educational grant from Vifor Pharma

Case-based interactive panel discussion – management of iron deficiency

Event : ESC Congress 2019

  • Session : Hyperkalaemia and iron deficiency management in 2019 – Making the case for better outcomes and quality of life
  • Speaker : S Anker (Berlin,DE), T McDonagh (London,GB), S von Haehling (Berlin,DE)
  • Organised by Charité Universitätsmedizin Berlin, supported by an unrestricted educational grant from Vifor Pharma

ESC Heart Failure – Open Access Journal

Event : Heart Failure 2019

  • Session : HFA General Assembly
  • Speaker : S Anker (Berlin,DE)

Evidence, guidelines, clinical practice – The evolving role of cardiologists in the SGLT2 inhibitor era

Event : ESC Congress 2019

  • Session : Evidence, guidelines, clinical practice – The evolving role of cardiologists in the SGLT2 inhibitor era
  • Speaker : N Marx (Aachen,DE), S Anker (Berlin,DE)
  • Sponsored by The Boehringer Ingelheim and Eli Lilly and Company Alliance

Hyperkalaemia: a barrier to guideline-recommended RAASi therapy?

Event : ESC Congress 2019

  • Session : Towards the state-of-the-art potassium control in patients with heart failure: are we there yet? (EBAC accredited)
  • Speaker : S Anker (Berlin,DE)
  • Supported by an unrestricted educational grant from AstraZeneca

Introduction

Event : ESC Congress 2019

  • Session : Towards the state-of-the-art potassium control in patients with heart failure: are we there yet? (EBAC accredited)
  • Speaker : S Anker (Berlin,DE)
  • Supported by an unrestricted educational grant from AstraZeneca

Introduction - Current challenges and innovations in the treatment of mitral and tricuspid regurgitation.

Event : Heart Failure 2019

  • Session : Current challenges and innovations in the treatment of mitral and tricuspid regurgitation
  • Speaker : S Anker (Berlin,DE)
  • Organised by Charité Berlin, supported with an educational grant from Edwards

Panel discussion - Innovative devices to better treat heart failure patients.

Event : Heart Failure 2019

  • Session : Innovative devices to better treat heart failure patients
  • Speaker : S Anker (Berlin,DE), A Coats (Warwickshire,GB), P Ponikowski (Wroclaw,PL), H Sievert (Frankfurt,DE), MJ Swaans (Hedel,NL), K Witte (Leeds,GB)
  • Organised by Charité Berlin, supported with educational grants provided by Bioventrix, Cardiac Dimensions and Respicardia

Panel discussion and conclusion - Current challenges and innovations in the treatment of mitral and tricuspid regurgitation.

Event : Heart Failure 2019

  • Session : Current challenges and innovations in the treatment of mitral and tricuspid regurgitation
  • Speaker : S Anker (Berlin,DE), M Chrissoheris (Athens,GR), K Spargias (Athens,GR), G Hasenfuss (Goettingen,DE), F Maisano (Zurich,CH), R Von Bardeleben (Mainz,DE)
  • Organised by Charité Berlin, supported with an educational grant from Edwards

Positioning SLG-2 inhibitors in the treatment of diabetes in heart failure.

Event : Heart Failure 2019

  • Session : Focus on diabetes in heart failure
  • Speaker : S Anker (Berlin,DE)

Potassium and heart failure.

Event : Webinar 2019

  • Session : HFA Webinars 2019
  • Speaker : S Anker (Berlin,DE), J Cleland (Glasgow,GB), M Lainscak (Murska Sobota,SI), F Zannad (Vandoeuvre,FR)

Potassium binders.

Event : Heart Failure 2019

  • Session : Emerging therapies in heart failure
  • Speaker : S Anker (Berlin,DE)
  • Joint Session with the working group on pharmacotherapy of the ESC

State of the Art -Diabetes and heart failure: complex interactions

Event : ESC Congress 2019

  • Session : Heart failure and diabetes: what is on the horizon
  • Speaker : S Anker (Berlin,DE)

The SGLT2 inhibitor era: what more can we expect?

Event : ESC Congress 2019

  • Session : SGLT2 inhibitors in clinical cardiology: modern-day cardiovascular management in patients with type 2 diabetes
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by The Boehringer Ingelheim, Eli Lilly and Company Alliance

Towards the state-of-the-art potassium management in heart failure: opportunities and challenges.

Event : ESC Congress 2019

  • Session : Towards the state-of-the-art potassium control in patients with heart failure: are we there yet? (EBAC accredited)
  • Speaker : S Anker (Berlin,DE), M Kosiborod (Kansas,US), M Lainscak (Murska Sobota,SI)
  • Supported by an unrestricted educational grant from AstraZeneca

Welcome and introduction

Event : ESC Congress 2019

  • Session : Hyperkalaemia and iron deficiency management in 2019 – Making the case for better outcomes and quality of life
  • Speaker : S Anker (Berlin,DE)
  • Organised by Charité Universitätsmedizin Berlin, supported by an unrestricted educational grant from Vifor Pharma

Welcome and introduction

Event : ESC Congress 2019

  • Session : Evidence, guidelines, clinical practice – The evolving role of cardiologists in the SGLT2 inhibitor era
  • Speaker : N Marx (Aachen,DE), S Anker (Berlin,DE)
  • Sponsored by The Boehringer Ingelheim and Eli Lilly and Company Alliance

What do the guidelines say?

Event : Heart Failure 2019

  • Session : Guidelines in Daily Practice I: Potassium binders
  • Speaker : S Anker (Berlin,DE)

A patient with iron deficiency - Wrap-up and take home message

Event : Heart Failure 2018

  • Session : Guidelines in daily practice I - Iron deficiency
  • Speaker : S Anker (Berlin,DE)

Case1: my stable Heart Failure with reduced Ejection Fraction (HFrEF) patient: I should start an ARNI immediately!

Event : Heart Failure 2018

  • Session : Heart failure case debates with the experts
  • Speaker : M Packer (Dallas,US), S Anker (Berlin,DE)
  • Organised by Medscape Education, supported with an educational grant by Novartis

Chronic heart failure - Focus on comorbitidies.

Event : ESC Congress 2018

  • Session : The future of heart failure therapy - When failure is not an option
  • Speaker : S Anker (Berlin,DE)
  • Heart Failure Association (HFA)

Close - Reducing premature cardiovascular mortality in patients with type 2 diabetes: best practice in cardiology

Event : ESC Congress 2018

  • Session : Reducing premature cardiovascular mortality in patients with type 2 diabetes: best practice in cardiology
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Conclusion - Heart Failure (HF) case debates with the experts.

Event : Heart Failure 2018

  • Session : Heart failure case debates with the experts
  • Speaker : L Lund (Stockholm,SE), S Anker (Berlin,DE)
  • Organised by Medscape Education, supported with an educational grant by Novartis

ESC Heart Failure Open Access Journal Report.

Event : Heart Failure 2018

  • Session : HFA General Assembly
  • Speaker : S Anker (Berlin,DE)

Hyperkalaemia and iron deficiency in chronic heart failure – how important?

Event : ESC Congress 2018

  • Session : Co-morbidities in chronic heart failure – time for paradigm shifts in the management of hyperkalaemia and iron deficiency
  • Speaker : S Anker (Berlin,DE)
  • Organised by Charité supported with an educational grant from Vifor

Introduction and welcome - Reducing premature cardiovascular mortality in patients with type 2 diabetes: best practice in cardiology

Event : ESC Congress 2018

  • Session : Reducing premature cardiovascular mortality in patients with type 2 diabetes: best practice in cardiology
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Iron deficiency in heart failure: future directions - Discussions and questions.

Event : Heart Failure 2018

  • Session : Iron deficiency in heart failure: future directions
  • Speaker : P Ponikowski (Wroclaw,PL), S Anker (Berlin,DE), W Doehner (Berlin,DE)
  • Sponsored by Vifor Pharma

Iron deficiency in heart failure: future directions.

Event : Heart Failure 2018

  • Session : Iron deficiency in heart failure: future directions
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

Iron deficiency: an important comorbidity - Conclusion.

Event : Heart Failure 2018

  • Session : Iron deficiency: an important comorbidity
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

Iron deficiency: an important comorbidity - Discussion and questions.

Event : Heart Failure 2018

  • Session : Iron deficiency: an important comorbidity
  • Speaker : S Anker (Berlin,DE), P Van Der Meer (Groningen,NL), CS Lam (Singapore,SG), EA Jankowska (Wroclaw,PL)
  • Sponsored by Vifor Pharma

Iron supplementation to improve outcomes?

Event : Heart Failure 2018

  • Session : Iron deficiency in heart failure
  • Speaker : S Anker (Berlin,DE)

Management of FMR and TR: what do the guidelines say?

Event : Heart Failure 2018

  • Session : Functional mitral and tricuspid regurgitation: will novel transcatheter options redefine the landscape?
  • Speaker : S Anker (Berlin,DE)
  • Organised by Charité Berlin, supported with an educational grant by Edwards Lifesciences

Management of patients with HFmrEF - How is it different from "r" and "p"?

Event : ESC Congress 2018

  • Session : Expert Advice - Diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF)
  • Speaker : S Anker (Berlin,DE)

Ongoing clinical trials in type 2 diabetes with heart failure

Event : Heart Failure 2018

  • Session : Diabetes and heart failure - A 21st century global challenge
  • Speaker : S Anker (Berlin,DE)

Open Q&A

Event : ESC Congress 2018

  • Session : Reducing premature cardiovascular mortality in patients with type 2 diabetes: best practice in cardiology
  • Speaker : S Anker (Berlin,DE), J Butler (Atlanta,US)
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Panel discussion - Baroreflex activation therapy for resistant hypertension and heart failure: the new piece in the puzzle.

Event : ESC Congress 2018

  • Session : Baroreflex activation therapy for resistant hypertension and heart failure: the new piece in the puzzle
  • Speaker : S Anker (Berlin,DE), M Metra (Brescia,IT), G Filippatos (Athens,GR), A Coats (Warwickshire,GB), J Bauersachs (Hannover,DE), A Pathak (Toulouse,FR)
  • Organised by Charité supported with an educational grant from CVRx

Panel discussion and close - Hyperkalaemia and iron deficiency: time for a paradigm change.

Event : ESC Congress 2018

  • Session : Co-morbidities in chronic heart failure – time for paradigm shifts in the management of hyperkalaemia and iron deficiency
  • Speaker : J Butler (Atlanta,US), G Filippatos (Athens,GR), S Anker (Berlin,DE), P Van Der Meer (Groningen,NL), I Pina (Detroit,US)
  • Organised by Charité supported with an educational grant from Vifor

Panel discussion.

Event : Heart Failure 2018

  • Session : Functional mitral and tricuspid regurgitation: will novel transcatheter options redefine the landscape?
  • Speaker : W Abraham (Columbus,US), S Anker (Berlin,DE), F Maisano (Zurich,CH), U Schaefer (,DE), ML Enriquez-Sarano (Rochester,US), P Seferovic (Belgrade,RS)
  • Organised by Charité Berlin, supported with an educational grant by Edwards Lifesciences

Question period.

Event : Heart Failure 2018

  • Session : Heart failure case debates with the experts
  • Speaker : S Anker (Berlin,DE)
  • Organised by Medscape Education, supported with an educational grant by Novartis

The ESC 2016 Heart Failure Guidelines: what is the recommendation for iron deficiency and why?

Event : Heart Failure 2018

  • Session : Iron deficiency: an important comorbidity
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

The v-wave shunt for left atrial decompression in patients with advanced chronic heart failure: fim safety and feasibility study

Event : Heart Failure 2018

  • Session : Late breaking trial III - Innovative and device therapy
  • Speaker : S Anker (Berlin,DE)

Welcome and introduction - Baroreflex activation therapy in Heart Failure with reduced Ejection Fraction (HFrEF): overcoming the limits of currently available therapies.

Event : Heart Failure 2018

  • Session : Baroreflex activation therapy in Heart Failure with reduced Ejection Fraction (HFrEF): overcoming the limits of currently available therapies
  • Speaker : S Anker (Berlin,DE), G Filippatos (Athens,GR)
  • Sponsored by Charité Berlin

Advances in pharmacological treatment.

Event : EuroEcho 2017

  • Session : Heart failure: imaging matters
  • Speaker : S Anker (Berlin,DE)

Changing the treatment paradigm of hyperkalaemia management to enable and optimise renin-angiotensin-aldosterone system inhibitor therapy.

Event : ESC Congress 2017

  • Session : Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma

Discussion - When to optimize heart failure treatment ?

Event : ESC Congress 2017

  • Session : When to optimize heart failure treatment?
  • Speaker : S Anker (Berlin,DE), M Boehm (Homburg,DE), M Cowie (London,GB), M Komajda (Paris,FR), Y Lopatin (Volgograd,RU)
  • Sponsored by SERVIER

Discussion: iron deficiency in patients with heart failure: implementing the guidelines in your clinical practice.

Event : Heart Failure 2017

  • Session : Iron deficiency in patients with heart failure: implementing the guidelines in your clinical practice
  • Speaker : P Van Der Meer (Groningen,NL), T McDonagh (London,GB), S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

ESC Heart Failure – Open Access Journal.

Event : Heart Failure 2017

  • Session : HFA General Assembly
  • Speaker : S Anker (Berlin,DE)

Functional mitral regurgitation: the road ahead.

Event : Heart Failure 2017

  • Session : Valvular disease is myocardial disease
  • Speaker : S Anker (Berlin,DE)

Future treatment of chronic heart failure

Event : ESC Congress 2017

  • Session : The future of heart failure therapy
  • Speaker : S Anker (Berlin,DE)
  • Heart Failure Association (ESC)

Heart failure & diabetes: time for a more unified approach.

Event : ESC Congress 2017

  • Session : Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure (EBAC Accredited)
  • Speaker : S Anker (Berlin,DE)
  • Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Boehringer Ingelheim/Lilly

Introduction - When to optimize heart failure treatment?

Event : ESC Congress 2017

  • Session : When to optimize heart failure treatment?
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by SERVIER

Panel discussion; SGLT2 in clinical cardiology.

Event : ESC Congress 2017

  • Session : Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure (EBAC Accredited)
  • Speaker : S Anker (Berlin,DE), N Sattar (Glasgow,GB), J Deanfield (,GB), D Fitchett (Toronto,CA)
  • Organised by Physicians' Academy for Cardiovascular Education, supported with an educational grant by Boehringer Ingelheim/Lilly

Questions & answers.

Event : Heart Failure 2017

  • Session : Tricuspid regurgitation in heart failure: how to treat it?
  • Speaker : S Anker (Berlin,DE), L Labrousse (Pessac,FR), A Latib (Milan,IT)
  • Sponsored by Charité Universitätsmedizin Berlin

Sarcopenia and frailty in heart failure: from skeletal muscle to fat and back.

Event : Heart Failure 2017

  • Session : Attention needed for comorbidities
  • Speaker : S Anker (Berlin,DE)

State of the Art: glucose-lowering drugs and cardiovascular outcomes

Event : ESC Congress 2017

  • Session : Heart failure and diabetes: a treacherous combination
  • Speaker : S Anker (Berlin,DE)

The problems of cachexia, sarcopenia and frailty in heart failure: treatment options.

Event : Heart Failure 2017

  • Session : How should comorbidities in heart failure be treated?
  • Speaker : S Anker (Berlin,DE)

Treatment strategies to manage hyperkalemia and control potassium levels.

Event : Heart Failure 2017

  • Session : Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma / Vifor Fresenius Medical Care Renal Pharma

Tricuspid regurgitation in the heart failure population.

Event : Heart Failure 2017

  • Session : Tricuspid regurgitation in heart failure: how to treat it?
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Charité Universitätsmedizin Berlin

Welcome and introduction - Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension.

Event : ESC Congress 2017

  • Session : Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension
  • Speaker : S Anker (Berlin,DE), F Zannad (Vandoeuvre,FR)
  • Organised by Charité Medical School, supported with an educational grant by CVRx

Welcome and introduction.

Event : Heart Failure 2017

  • Session : Novel transcatheter options for functional mitral regurgitation in heart failure
  • Speaker : S Anker (Berlin,DE), W Abraham (Columbus,US)
  • Sponsored by Charité Universitätsmedizin Berlin

What went wrong in previous trials.

Event : Heart Failure 2017

  • Session : What a busy clinician should know about heart failure with preserved ejection fraction
  • Speaker : S Anker (Berlin,DE)

Controversies in heart failure - Conclusion

Event : ESC Congress 2016

  • Session : Controversies in heart failure
  • Speaker : S Anker (Berlin,DE)

Diabetes management in heart failure

Event : ESC Congress 2016

  • Session : Dealing with comorbidities in heart failure: the way forward to individualised medicine
  • Speaker : S Anker (Berlin,DE)

ESC Heart Failure.

Event : Heart Failure 2016

  • Session : HFA General Assembly
  • Speaker : S Anker (Berlin,DE)

Heart failure and diabetes

Event : ESC Congress 2016

  • Session : What a cardiologist should know about heart failure with comorbidities
  • Speaker : S Anker (Berlin,DE)
  • Organised by Heart Failure Assciation of the ESC

Importance of comorbidities.

Event : Heart Failure 2016

  • Session : The new ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Overview
  • Speaker : S Anker (Berlin,DE)

Interactive case discussion: what are the clinical implications of cardiovascular outcomes of SGLT2 inhibition?

Event : Heart Failure 2016

  • Session : Novel strategies for addressing diabetes & heart failure: evaluating cardiovascular outcomes
  • Speaker : S Anker (Berlin,DE), D Fitchett (Toronto,CA)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from Boehringer Ingelheim

Introduction.

Event : Heart Failure 2016

  • Session : Diabetes & heart failure: evaluating novel strategies to address outcomes
  • Speaker : S Anker (Berlin,DE)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from Boehringer Ingelheim

Introduction.

Event : Heart Failure 2016

  • Session : Novel strategies for addressing diabetes & heart failure: evaluating cardiovascular outcomes
  • Speaker : S Anker (Berlin,DE)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from Boehringer Ingelheim

Iron deficiency in chronic heart failure: reviewing the evidence.

Event : Heart Failure 2016

  • Session : Iron deficiency matters in chronic heart failure
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

Management of chronic heart failure: pharmacology

Event : ESC Congress 2016

  • Session : The new ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
  • Speaker : S Anker (Berlin,DE)

Panel discussion - Optimizing RAAS inhibitor therapy in heart failure and resistant hypertension: challenges and solutions.

Event : ESC Congress 2016

  • Session : Optimizing RAAS inhibitor therapy in heart failure and resistant hypertension: challenges and solutions
  • Speaker : F Zannad (Vandoeuvre,FR), S Anker (Berlin,DE), LM Ruilope (Madrid,ES), M Kosiborod (Kansas,US)
  • Organised by Lorraine University / Course Director: Dr. Faiez Zannad / Supported by an unrestricted educational grant from AstraZeneca

Panel discussion and audience Q&A: acute hemodynamic support options in Europe.

Event : ESC Congress 2016

  • Session : Acute hemodynamic support for impending, established cardiogenic shock & high risk PCI
  • Speaker : G Dangas (New York,US), S Anker (Berlin,DE), A Schaefer (Hannover,DE), WW O'Neill (Miami,US), B Schieffer (Marburg,DE), R Westenfeld (Dusseldorf,DE), JPS Henriques (Amsterdam,NL), K Ibrahim (Dresden,DE)
  • Sponsored by Abiomed

Panel discussion.

Event : Heart Failure 2016

  • Session : Diabetes & heart failure: evaluating novel strategies to address outcomes
  • Speaker : S Anker (Berlin,DE), A Voors (Groningen,NL), D Fitchett (Toronto,CA), N Sattar (Glasgow,GB)
  • Organised by the Physicians Academy for Cardiovascular Education (PACE) Foundation / Course Director: Prof Adriaan A Voors / Supported by an unrestricted educational grant from Boehringer Ingelheim

RAAS inhibition in heart failure: are we hitting the target?

Event : ESC Congress 2016

  • Session : Optimizing RAAS inhibitor therapy in heart failure and resistant hypertension: challenges and solutions
  • Speaker : S Anker (Berlin,DE)
  • Organised by Lorraine University / Course Director: Dr. Faiez Zannad / Supported by an unrestricted educational grant from AstraZeneca

Reaching the next level of drug development for heart failure: targetting mitochondria.

Event : Heart Failure 2016

  • Session : Targeting mitochondria to improve outcomes in heart failure
  • Speaker : S Anker (Berlin,DE)
  • Organised by Charité Medical School Berlin, supported by an unrestricted educational grant from Stealth Peptides

SGLT2 inhibitors studied in T2DM.

Event : Heart Failure 2016

  • Session : What heart failure specialists can learn from trials in other disease areas
  • Speaker : S Anker (Berlin,DE)

Ularitide.

Event : Heart Failure 2016

  • Session : Drugs in the pipeline for acute heart failure
  • Speaker : S Anker (Berlin,DE)

What went wrong in previous trials.

Event : Heart Failure 2016

  • Session : What a clinician should know about heart failure with preserved ejection fraction
  • Speaker : S Anker (Berlin,DE)

Ferric carboxymaltose in iron deficient heart failure patients: a meta-analysis on individual patient data

Event : ESC Congress 2015

  • Session : Changes in heart failure, epidemiology and management
  • Speaker : S Anker (Berlin,DE)

Improving outcome with intravenous iron in iron deficient heart failure patients.

Event : Heart Failure 2015

  • Session : Changing conventions – Intravenous iron in heart failure
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

Improving outcome with intravenous iron in iron deficient heart failure patients.

Event : ESC Congress 2015

  • Session : Intravenous iron in heart failure – Improving patient’s outcomes
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Charité

Improving outcome with intravenous iron in iron deficient heart failure patients.

Event : Heart Failure 2015

  • Session : Intravenous iron in heart failure – Improving patient’s outcomes
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

Initial clinical trial results with Bendavia in heart failure.

Event : Heart Failure 2015

  • Session : Mitochondria in heart failure: a new target for therapy and recent first results
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Charité University Berlin and Stealth Peptides

LV reconstruction.

Event : ESC Congress 2015

  • Session : Devices for heart failure: the pipeline
  • Speaker : S Anker (Berlin,DE)

New natriuretric peptides in trials: ularitide & C/D-NP.

Event : ESC Congress 2015

  • Session : Natriuretric peptides as a therapeutic approach in chronic and acute heart failure
  • Speaker : S Anker (Berlin,DE)

Now what? Treatment of intravenous iron improves patients’ outcome.

Event : ESC Congress 2015

  • Session : Changing conventions - Intravenous iron in heart failure
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Charité

Panel discussion - Changing conventions - Intravenous iron in heart failure.

Event : ESC Congress 2015

  • Session : Changing conventions - Intravenous iron in heart failure
  • Speaker : S Anker (Berlin,DE), P Ponikowski (Wroclaw,PL), G Filippatos (Athens,GR), J Cleland (Glasgow,GB)
  • Sponsored by Charité

Philip Poole Wilson Lecture: announcement of a new HFA initiative.

Event : Heart Failure 2015

  • Session : Inaugural Session
  • Speaker : S Anker (Berlin,DE)

Team #2 - RAASi should be stopped in HF patients.

Event : Heart Failure 2015

  • Session : The RAASi debate: should RAAS blockade continue with a declining eGFR?
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by ZS Pharma, Inc.

Time to first event versus repeated event analysis - Who wins the game?

Event : ESC Congress 2015

  • Session : Trials and statistics are easy! A guide for the clinical cardiologist
  • Speaker : S Anker (Berlin,DE)

Ularitide: this time it is different.

Event : Heart Failure 2015

  • Session : Acute heart failure: novel therapies on the horizon
  • Speaker : S Anker (Berlin,DE)

Worsening heart failure in patients with coronary artery disease: pathophysiology revisited.

Event : Heart Failure 2015

  • Session : Novel oral anticoagulant use in patients with heart failure: present and future perspectives
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Bayer Healthcare

Implication of iron deficiency in HF clinical management.

Event : ESC Congress 2014

  • Session : Iron deficiency in heart failure – The relevance for the patient
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

Introduction to the session.

Event : ESC Congress 2014

  • Session : Sleep in heart failure - a restless problem and therapeutic options
  • Speaker : S Anker (Berlin,DE)

Natriuretic peptides.

Event : ESC Congress 2014

  • Session : Emerging therapies in acute heart failure
  • Speaker : S Anker (Berlin,DE)

The RAASi Debate – Team #2 Arguments: RAASI should be stopped in HF and CKD patients.

Event : ESC Congress 2014

  • Session : The RAASi debate: should RAAS blockade continue with a declining eGFR?
  • Speaker : S Anker (Berlin,DE), B Palmer (Dallas,US)
  • Sponsored by ZS Pharma, Inc.

The RAASi Debate – Team #2 challenges team #1

Event : ESC Congress 2014

  • Session : The RAASi debate: should RAAS blockade continue with a declining eGFR?
  • Speaker : S Anker (Berlin,DE), B Palmer (Dallas,US)
  • Sponsored by ZS Pharma, Inc.

Introduction: can we improve morbidity and mortality with tailored strategies in acute heart failure?

Event : ESC Congress 2013

  • Session : Can we improve morbidity and mortality with tailored strategies in acute heart failure?
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by theheart.org / Medscape Education

Iron and erythropoiesis stimulating agents.

Event : ESC Congress 2013

  • Session : Treatment of chronic heart failure: update 2013
  • Speaker : S Anker (Berlin,DE)

Iron deficiency – New therapeutic target in heart failure.

Event : ESC Congress 2013

  • Session : Iron deficiency in heart failure – From evidence to practice
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma

Novel natriuretic peptides.

Event : ESC Congress 2013

  • Session : Emerging therapies in acute heart failure
  • Speaker : S Anker (Berlin,DE)

Panel.

Event : ESC Congress 2013

  • Session : Emerging therapies in acute heart failure
  • Speaker : S Anker (Berlin,DE), M Metra (Brescia,IT), P Ponikowski (Wroclaw,PL), JR Teerlink (San Francisco,US)

Towards tailored management of heart failure patients with co-morbidities (SICA-HF).

Event : ESC Congress 2013

  • Session : Towards evidence based therapies and care - EU funded collaborative cardiovascular disease research
  • Speaker : S Anker (Berlin,DE)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are